PAOG Announces OTC Markets Current Information Reporting Standard

Sandusky, OH -- September 2, 2020 -- InvestorsHub NewsWire -- PAO Group, Inc. (USOTC: PAOG) today announced having updated all formerly delinquent financial reports.  PAOG has being reinstated to the OTC Markets “Current Information” reporting standard.

PAOG recently executed two acquisitions as part of an overall business revitalization strategy bringing the company into the cannabis biopharmaceutical sector. The company acquired a cannabis cultivation business from Puration, Inc. (PURA).  From Kali-Extracts (KALY), PAOG acquired a proprietary CBD extract derived from a patented extraction process and formulated for the treatment of respiratory disorders.

Goldman Small Cap Research is anticipated to update a recently published analyst report now that PAOG has achieved the "Current Information" standard.

See the current Goldman Small Cap Research Analyst Report:
Under The Radar CBD Pharma Player Could Offer Major Upside

www.paogroupinc.com.

­Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

CONTACT INFORMATION
Contact Us:
Jim DiPrima
888-272-6472
[e-mail]